US6374762B1
(en)
*
|
1997-10-27 |
2002-04-23 |
Correct Craft, Inc. |
Water sport towing apparatus
|
US6462053B1
(en)
*
|
1999-08-20 |
2002-10-08 |
Banyu Pharmaceutical Co., Ltd. |
Spiro compounds
|
US6803372B2
(en)
*
|
1999-08-20 |
2004-10-12 |
Banyu Pharmaceutical Co., Ltd. |
Spiro compounds
|
JP2004510736A
(ja)
*
|
2000-10-03 |
2004-04-08 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
アルコール中毒治療における神経ペプチドy拮抗物質の使用
|
EP1695977A3
(en)
*
|
2000-12-12 |
2006-09-20 |
Neurogen Corporation |
Spiro [isobenzofuran-1,4'piperidin]-3-ones and 3H-spiroisobenzofuran-1, 4'-piperidines
|
DE60115092T2
(de)
|
2000-12-12 |
2006-03-30 |
Neurogen Corp., Brandford |
Spiro[isobenzofuran-1,4'-piperidin]-3-one und 3h-spiroisobenzofuran-1,4'-piperidine
|
ATE413880T1
(de)
|
2000-12-21 |
2008-11-15 |
Schering Corp |
Heteroaryl-harnstoff-neuropeptid-y-y5-rezeptor- antagonisten
|
US6946476B2
(en)
|
2000-12-21 |
2005-09-20 |
Schering Corporation |
Heteroaryl urea neuropeptide Y Y5 receptor antagonists
|
US6924291B2
(en)
|
2001-01-23 |
2005-08-02 |
Merck & Co., Inc. |
Process for making spiro isobenzofuranone compounds
|
WO2002094825A1
(fr)
*
|
2001-05-22 |
2002-11-28 |
Banyu Pharmaceutical Co., Ltd. |
Nouveau derive de spiropiperidine
|
EP1470129B1
(en)
*
|
2001-07-24 |
2009-01-28 |
Merck & Co., Inc. |
Radiolabeled neuropeptide y y5 receptor antagonists
|
ATE427935T1
(de)
*
|
2001-08-07 |
2009-04-15 |
Banyu Pharma Co Ltd |
Spiro isobenzofurane als neuropeptid y rezeptor antagonisten
|
WO2003051397A1
(en)
*
|
2001-12-17 |
2003-06-26 |
Merck & Co., Inc. |
Neuropeptide y5 receptor antagonists for treating depression, anxiety and dementia
|
JP2005517654A
(ja)
*
|
2001-12-17 |
2005-06-16 |
メルク エンド カムパニー インコーポレーテッド |
日周期リズム障害の治療方法
|
US6605720B1
(en)
|
2002-01-28 |
2003-08-12 |
Merck & Co., Inc. |
Process for making spirolactone compounds
|
NZ534757A
(en)
*
|
2002-03-12 |
2006-07-28 |
Merck & Co Inc |
Substituted amides
|
JP4522853B2
(ja)
|
2002-06-27 |
2010-08-11 |
シェーリング コーポレイション |
肥満の処置のための選択的メラニン濃縮ホルモンレセプターアンタゴニストとしてのスピロ置換ピペリジン
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
CN1678608A
(zh)
*
|
2002-07-02 |
2005-10-05 |
先灵公司 |
新的神经肽yy5受体拮抗剂
|
US20050288213A1
(en)
*
|
2002-07-18 |
2005-12-29 |
Macneil Douglas J |
Combination therapy for the treatment of obesity
|
RU2005115087A
(ru)
*
|
2002-10-18 |
2006-01-20 |
Мерк энд Ко., Инк. (US) |
Способ получения соединений спиролактона
|
ATE433971T1
(de)
|
2002-11-29 |
2009-07-15 |
Banyu Pharma Co Ltd |
Neue azolderivate
|
US20040122033A1
(en)
*
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
AU2003290323A1
(en)
*
|
2002-12-24 |
2004-07-22 |
Biofocus Plc |
Compound libraries of 2h-spiro (isoquinoline-1, -piperidine derivatives and related compounds for targetting compounds capable of binding to the g-protein receptor
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
AR044283A1
(es)
*
|
2003-05-19 |
2005-09-07 |
Merck & Co Inc |
Procedimeinto para preparar compuestos de espirolactona
|
WO2004110368A2
(en)
*
|
2003-06-06 |
2004-12-23 |
Merck & Co., Inc. |
Combination therapy for the treatment of hypertension
|
US20060148721A1
(en)
*
|
2003-06-06 |
2006-07-06 |
Erondu Ngozi E |
Combination therapy for the treatment of dyslipidemia
|
US20070099884A1
(en)
*
|
2003-06-06 |
2007-05-03 |
Erondu Ngozi E |
Combination therapy for the treatment of diabetes
|
WO2005028438A1
(ja)
|
2003-09-22 |
2005-03-31 |
Banyu Pharmaceutical Co., Ltd. |
新規ピペリジン誘導体
|
US20050069244A1
(en)
*
|
2003-09-25 |
2005-03-31 |
Miguel Dajer |
Flexible distributed wireless signal system and method
|
JP2007506728A
(ja)
*
|
2003-09-26 |
2007-03-22 |
ファイザー・プロダクツ・インク |
概日リズム障害を治療するためのnpyy5受容体アンタゴニストの使用
|
WO2005030210A1
(en)
*
|
2003-09-26 |
2005-04-07 |
Pfizer Products Inc. |
Treatment of neurological disorders related to rapid eye movement (rem) sleep disturbances with npy y5 receptor antagonists
|
US20080255216A1
(en)
|
2004-03-29 |
2008-10-16 |
Aster Susan D |
Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1
|
EP2305352A1
(en)
|
2004-04-02 |
2011-04-06 |
Merck Sharp & Dohme Corp. |
5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
|
BRPI0510273A
(pt)
|
2004-05-25 |
2007-10-30 |
Pfizer Prod Inc |
derivados de tetraazabenzo[e]azuleno e análogos destes
|
JP2008509146A
(ja)
|
2004-08-06 |
2008-03-27 |
メルク エンド カムパニー インコーポレーテッド |
11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−1の阻害剤としてのスルホニル化合物
|
US7786141B2
(en)
*
|
2004-08-19 |
2010-08-31 |
Vertex Pharmaceuticals Incorporated |
Dihydrospiroindene modulators of muscarinic receptors
|
JP2008510728A
(ja)
|
2004-08-19 |
2008-04-10 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ムスカリン受容体のモジュレーター
|
WO2006022454A1
(ja)
|
2004-08-27 |
2006-03-02 |
Ono Pharmaceutical Co., Ltd |
塩基性基を含有する化合物およびその用途
|
DE602005014124D1
(de)
*
|
2004-09-07 |
2009-06-04 |
Banyu Pharma Co Ltd |
Carbamoylsubstituiertes spiro-derivat
|
US8394765B2
(en)
*
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
EP1814590B2
(en)
|
2004-11-01 |
2013-12-11 |
Amylin Pharmaceuticals, Inc. |
Treatment of obesity and related disorders
|
WO2006058303A2
(en)
*
|
2004-11-29 |
2006-06-01 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
CA2595855C
(en)
|
2005-01-25 |
2017-07-04 |
Synta Pharmaceuticals Corp. |
Pyrazine compounds for inflammation and immune-related uses
|
US20090286723A1
(en)
|
2005-02-11 |
2009-11-19 |
Amylin Pharmaceuticals, Inc. |
Hybrid Polypeptides with Selectable Properties
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
US20060270650A1
(en)
*
|
2005-05-26 |
2006-11-30 |
Macneil Tanya |
Combination therapy for the treatment of obesity
|
ES2574014T3
(es)
|
2005-05-30 |
2016-06-14 |
Msd K.K. |
Derivado de piperidina novedoso
|
WO2007016028A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Merck & Co., Inc. |
Synthesis and crystalline forms of npy5 antagonist
|
EP1916239A4
(en)
|
2005-08-10 |
2009-10-21 |
Banyu Pharma Co Ltd |
PYRIDONE COMPOUND
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
EP1921065B1
(en)
|
2005-08-24 |
2010-10-20 |
Banyu Pharmaceutical Co., Ltd. |
Phenylpyridone derivative
|
WO2007029847A1
(ja)
|
2005-09-07 |
2007-03-15 |
Banyu Pharmaceutical Co., Ltd. |
二環性芳香族置換ピリドン誘導体
|
JP2009507800A
(ja)
|
2005-09-09 |
2009-02-26 |
ユーロ−セルティーク エス.エイ. |
縮合およびスピロ環化合物ならびにその使用
|
EP1940842B1
(en)
|
2005-09-29 |
2012-05-30 |
Merck Sharp & Dohme Corp. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
BRPI0617621A2
(pt)
|
2005-10-21 |
2011-08-02 |
Novartis Ag |
combinação de compostos orgánicos
|
AU2006307046A1
(en)
|
2005-10-27 |
2007-05-03 |
Msd K.K. |
Novel benzoxathiin derivative
|
MY146564A
(en)
|
2005-11-10 |
2012-08-30 |
Msd Kk |
Aza-substituted spiro derivatives
|
ES2407115T3
(es)
|
2005-11-18 |
2013-06-11 |
Ono Pharmaceutical Co., Ltd. |
Compuesto que contiene un grupo básico y uso del mismo
|
EP1801098A1
(en)
|
2005-12-16 |
2007-06-27 |
Merck Sante |
2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
|
WO2007076070A2
(en)
*
|
2005-12-22 |
2007-07-05 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
KR20080098070A
(ko)
*
|
2006-02-22 |
2008-11-06 |
버텍스 파마슈티칼스 인코포레이티드 |
무스카린성 수용체의 조절제로서의 스피로 축합된 피페리딘
|
KR20080094964A
(ko)
*
|
2006-02-22 |
2008-10-27 |
버텍스 파마슈티칼스 인코포레이티드 |
무스카린성 수용체의 조절제
|
CA2648036C
(en)
|
2006-03-31 |
2012-05-22 |
Janssen Pharmaceutica N.V. |
Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
|
JP5257068B2
(ja)
|
2006-05-16 |
2013-08-07 |
小野薬品工業株式会社 |
保護されていてもよい酸性基を含有する化合物およびその用途
|
JP2009542670A
(ja)
*
|
2006-06-29 |
2009-12-03 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ムスカリン受容体の調節剤
|
AU2007284548A1
(en)
*
|
2006-08-15 |
2008-02-21 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
JP2010501561A
(ja)
*
|
2006-08-18 |
2010-01-21 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ムスカリン受容体の調節剤
|
EP2698157B1
(en)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
WO2008038692A1
(fr)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
dÉrivÉ de diarylcÉtimine
|
EP2102207B1
(en)
*
|
2006-12-07 |
2010-06-02 |
F.Hoffmann-La Roche Ag |
Spiro-piperidine derivatives as via receptor antagonists
|
EP1935420A1
(en)
|
2006-12-21 |
2008-06-25 |
Merck Sante |
2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
|
JP2010513385A
(ja)
*
|
2006-12-22 |
2010-04-30 |
エフ.ホフマン−ラ ロシュ アーゲー |
スピロ−ピペリジン誘導体
|
CN101563324A
(zh)
|
2006-12-22 |
2009-10-21 |
弗·哈夫曼-拉罗切有限公司 |
螺-哌啶衍生物
|
ATE486877T1
(de)
|
2006-12-29 |
2010-11-15 |
Hoffmann La Roche |
Azaspiroderivate
|
AU2008233662B2
(en)
|
2007-04-02 |
2012-08-23 |
Msd K.K. |
Indoledione derivative
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
US7973162B2
(en)
*
|
2007-10-03 |
2011-07-05 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
BRPI0722276A2
(pt)
*
|
2007-11-14 |
2014-04-22 |
Amylin Pharmaceuticals Inc |
Métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
|
WO2009070583A1
(en)
*
|
2007-11-30 |
2009-06-04 |
Wyeth |
Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
|
CA2706866A1
(en)
*
|
2007-11-30 |
2009-06-04 |
Biotie Therapies Gmbh |
Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
|
CA2714617A1
(en)
|
2008-03-06 |
2009-09-11 |
Banyu Pharmaceutical Co., Ltd. |
Alkylaminopyridine derivative
|
WO2009111868A1
(en)
*
|
2008-03-11 |
2009-09-17 |
University Health Network |
Method of treating cancer using a neuropeptide y 5r (np y5r) antagonist
|
US20110015198A1
(en)
|
2008-03-28 |
2011-01-20 |
Banyu Pharmaceutical Co., Inc. |
Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
EP3239170B1
(en)
|
2008-06-04 |
2019-03-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
EP2301936A1
(en)
|
2008-06-19 |
2011-03-30 |
Banyu Pharmaceutical Co., Ltd. |
Spirodiamine-diarylketoxime derivative
|
US9371311B2
(en)
|
2008-06-30 |
2016-06-21 |
Janssen Pharmaceutica Nv |
Benzoimidazol-2-yl pyrimidine derivatives
|
EP3241839B1
(en)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
EP2319841A1
(en)
|
2008-07-30 |
2011-05-11 |
Msd K.K. |
(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
|
CA2741125A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
CA2741644C
(en)
|
2008-10-30 |
2013-05-07 |
Merck Sharp & Dohme Corp. |
Isonicotinamide orexin receptor antagonists
|
WO2010051206A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
CA2743489A1
(en)
|
2008-11-17 |
2010-05-20 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
CA2741839A1
(en)
*
|
2008-11-21 |
2010-05-27 |
Pfizer Inc. |
1-oxa-8-azaspiro [4,5] decane-8-carboxamide compounds as faah inhibitors
|
EP2379547A1
(en)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
US20110243940A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Bicyclic pyranone derivatives and methods of use thereof
|
WO2010138833A1
(en)
|
2009-05-29 |
2010-12-02 |
Wyeth |
SUBSTITUTED IMIDAZO[1,5-a]QUINOXALINES AS INHIBITORS OF PHOSPHODIESTERASE 10
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
US20120220567A1
(en)
|
2009-07-23 |
2012-08-30 |
Shipps Jr Gerald W |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
AU2010317842A1
(en)
|
2009-11-16 |
2012-07-12 |
Mellitech |
[1,5]-diazocin derivatives
|
EP2521721B1
(en)
|
2009-12-30 |
2014-10-01 |
Shanghai Fochon Pharmaceutical Co. Ltd |
3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
EP2563764B1
(en)
|
2010-04-26 |
2015-02-25 |
Merck Sharp & Dohme Corp. |
Novel spiropiperidine prolylcarboxypeptidase inhibitors
|
WO2011143057A1
(en)
|
2010-05-11 |
2011-11-17 |
Merck Sharp & Dohme Corp. |
Novel prolylcarboxypeptidase inhibitors
|
EP2571860A1
(en)
|
2010-05-21 |
2013-03-27 |
Pfizer Inc |
2-phenyl benzoylamides
|
WO2011156246A1
(en)
|
2010-06-11 |
2011-12-15 |
Merck Sharp & Dohme Corp. |
Novel prolylcarboxypeptidase inhibitors
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
EP2677869B1
(en)
|
2011-02-25 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
EP2680874A2
(en)
|
2011-03-04 |
2014-01-08 |
Pfizer Inc |
Edn3-like peptides and uses thereof
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
AU2013296470B2
(en)
|
2012-08-02 |
2016-03-17 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
AU2014219020A1
(en)
|
2013-02-22 |
2015-07-23 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
UY35370A
(es)
|
2013-03-06 |
2014-09-30 |
Janssen Pharmaceutica Nv |
Moduladores benzoimidazol-2-il pirimidina del receptor de histamina h4
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
JP6769963B2
(ja)
|
2014-08-29 |
2020-10-14 |
ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ |
α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤
|
US10076698B2
(en)
|
2016-05-17 |
2018-09-18 |
Sportsmedia Technology Corporation |
Automated or assisted umpiring of baseball game using computer vision
|
AU2017342083A1
(en)
|
2016-10-14 |
2019-04-11 |
Tes Pharma S.R.L. |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
|
EP3551176A4
(en)
|
2016-12-06 |
2020-06-24 |
Merck Sharp & Dohme Corp. |
ANTIDIABETIC HETEROCYCLIC COMPOUNDS
|
EP3558298A4
(en)
|
2016-12-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
ANTIDIABETIC SPIROCHROMAN COMPOUNDS
|
KR20210111248A
(ko)
|
2018-11-20 |
2021-09-10 |
테스 파마 에스.알.엘. |
α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제
|
WO2020167706A1
(en)
|
2019-02-13 |
2020-08-20 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
WO2021026047A1
(en)
|
2019-08-08 |
2021-02-11 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
CR20230089A
(es)
|
2020-08-18 |
2023-04-11 |
Merck Sharp & Dohme Llc |
Agonistas de bicicloheptano pirrolidina de los receptores de orexina
|